PORTLAND, Ore., Feb. 27, 2014 /PRNewswire/ -- Semler Scientific, Inc. (NASDAQ: SMLR), an emerging medical risk-assessment company whose mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services, today announced the closing of its previously announced initial public offering of 1,430,000 shares of its common stock offered at a price to the public of $7.00 per share. The gross proceeds to Semler from the initial public offering were $10,010,000, before deducting underwriting discounts and commissions and other offering expenses. Semler has granted the representative of the
underwriters a 45-day option to purchase up to 214,500 additional shares of common stock from Semler to cover over-allotments, if any.
Aegis Capital Corp. acted as sole book-running manager for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 20, 2014. This offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained by contacting the representative of the underwriters (as set forth below) or by accessing the SEC's website at www.sec.gov.
Aegis Capital Corp.
Prospectus Department
810 Seventh Avenue, 18th Floor
New York, NY 10019
telephone: 212-813-1010
e-mail: prospectus@aegiscap.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Semler Scientific, Inc.:
Semler Scientific, Inc. is an emerging medical risk-assessment company. Its mission is to develop, manufacture and market patented products that identify the risk profile of medical patients to allow healthcare providers to capture full reimbursement potential for their services. Semler's first patented and U.S. Food and Drug Administration, or FDA, cleared product, is FloChec™. FloChec™ is used in the office setting to allow providers to measure arterial blood flow in the extremities and is a useful tool for internists and primary care physicians for whom it was previously impractical to conduct blood flow measurements. FloChec™ received FDA 510(k) clearance in February 2010, Semler began Beta testing in the third quarter of 2010, and Semler began commercially
leasing FloChec™ in January 2011.
CONTACT:
Susan A. Noonan
S.A. Noonan Communications
susan@sanoonan.com
212 966 3650
SOURCE Semler Scientific, Inc.
